Eurozone private sector credit growth is picking up, which signals that households and businesses are more willing to borrow and invest again. That kind of backdrop often rewards fast growing companies where management is already confident about the road ahead. Investors who wait for absolute clarity can miss early moves. This article highlights three fast growing stocks with high insider ownership from the screener that fit this theme today.
The stocks covered below are only a small sample, and the full screen surfaced 106 more companies with equally compelling stories around fast growth and meaningful insider ownership that are not covered here. If you want to move quickly from ideas to a focused watchlist, head straight to the Fast Growing Stocks With High Insider Ownership screener to identify, filter and analyze the highest conviction opportunities that match your criteria.
Rubicon Research (NSEI:RUBICON)
Overview: Rubicon Research is a specialty pharmaceutical company headquartered in Mumbai that focuses on developing and commercialising differentiated prescription products, underpinned by proprietary drug delivery platforms like RubiReten and RubiSRL. Its core work in analgesics, cardiovascular and central nervous system therapies, nicotine replacement and other niche segments aligns directly with the screener theme because these specialty formulations can support rapid growth and are closely shaped by management and insider driven R&D decisions.
Operations: Rubicon Research currently generates all of its reported revenue, amounting to ₹19,358 million, from pharmaceutical products across generics, specialty drugs, active pharmaceutical ingredients and related services.
Market Cap: ₹301.1 billion
Rubicon Research gives you exposure to specialty pharma growth where the main engine is clearly defined: a focused pipeline of high value drugs built on proprietary RubiReten and RubiSRL platforms, backed by steady R&D spend of about 10% to 11% of revenue and a high product commercialisation rate. Recent full year revenue of ₹17,616.83 million and net income of ₹2,467.35 million, alongside Q1 FY2027 figures that show higher sales and earnings than the prior year period, underline why analysts expect strong earnings expansion and remain constructive on the stock. The trade off is rich valuation, execution risk across multiple manufacturing sites and reliance on complex, niche therapies. If you want fast growth with insider alignment, this is a story worth watching more closely.
Rubicon Research pairs a tightly focused pipeline with insider driven R&D decisions. Yet the real story may sit in how that growth profile stacks up against expectations. Get the full picture through the analyst forecasts for Rubicon Research
Privi Speciality Chemicals (BSE:530117)
Overview: Privi Speciality Chemicals is a Mumbai based supplier of aroma and fragrance ingredients such as ionones, terpenes, sandal products and galaxolide substitutes that go into everyday personal care, home care and fine fragrance products for customers in India and overseas. Its focus on high margin fragrance chemicals links directly to the Fast Growing Stocks With High Insider Ownership theme, because the same scent ingredients that support rising consumption of deodorants, detergents and shampoos can also support strong revenue and earnings growth when demand is robust.
Operations: Privi Speciality Chemicals currently generates all its reported revenue, totalling ₹26,710.93 million, from aromatic chemicals.
Market Cap: ₹135.1 billion
Privi Speciality Chemicals may warrant closer attention for investors seeking exposure to fragrance driven consumer products. The company focuses on high value aroma ingredients for global FMCG clients. Recent Q1 FY2027 results show higher sales, net income and EPS than a year earlier. Profitability metrics such as a 13.1% net margin and 23.7% ROE indicate that current growth is supported by solid economics. On the other hand, the shares trade at a premium valuation and the balance sheet carries meaningful debt, which could be a concern if demand softens or incentives change. A key consideration for investors is whether the core fragrance business can continue to perform strongly enough to support these expectations.
Privi Speciality Chemicals is riding high on rich margins and a premium share price, yet the real story may be how expectations stack up against reality in the analyst forecasts for Privi Speciality Chemicals
Bajel Projects (NSEI:BAJEL)
Overview: Bajel Projects is an EPC contractor that designs, builds and commissions extra high voltage transmission lines and power distribution infrastructure in India and overseas, giving you direct exposure to grid expansion and electrification projects where growth expectations are already high. The company’s core business in turnkey transmission and distribution work aligns closely with the Fast Growing Stocks With High Insider Ownership theme, as management leans into large Ultra Mega orders and international contracts that depend on confident execution and a strong medium term outlook.
Operations: Bajel Projects currently generates all of its reported revenue, totalling ₹27,508 million, from power transmission and power distribution projects.
Market Cap: ₹21.9 billion
Bajel Projects is worth a closer look if you want direct exposure to the build out of high voltage power networks, backed by management that is clearly leaning into growth. Ultra Mega and Mega EPC orders in India, along with new work in Egypt and a joint venture in Saudi Arabia, point to an expanding footprint in 400 to 765 kV transmission projects that can support rising earnings if margins keep improving. The valuation already prices in a lot of optimism and the balance sheet leans on external funding, so execution and cash generation matter. For investors, the key question is whether Bajel can convert this project pipeline and forecasted earnings momentum into the higher profitability and returns that many are already betting on.
Growth expectations around Bajel Projects are accelerating, yet few investors seem to connect that optimism with the detailed earnings outlook captured in the analyst forecasts for Bajel Projects, including one factor that could completely change the risk reward picture.
Seeking Fresh Alternatives Before They Fly
Markets move fast and fresh opportunities can slip away quickly. To get ahead of the next breakout while momentum still matters and before these ideas are widely noticed, consider acting early.
- Identify cash rich companies before momentum stories dominate the headlines by scanning the list of solid balance sheet and fundamentals (426 results) and shortlisting those that match your risk and return goals.
- Combine potential income and price momentum by checking the curated 409 dividend fortresses before yields change and more investors pursue the same payouts.
- Focus on future facing infrastructure themes at an early stage by reviewing the hand picked 55 AI infrastructure stocks while these stories remain less widely followed.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com